Patient: Age: 47 Sex: M MRN: SAMPLE PATIENT Order Number: 81200334 Completed: September 20, 2007 Received: September 20, 2007 Collected: September 20, 2007 Complete Male Hormones
Patient: SAMPLE PATIENT Comple te ID: Page 1 Male Hormones Steroidogenic Pathway At-A-Glance Glucocorticoids (Catabolic) Androgens (Anabolic) Pregnenolone CYPc17 17-OH-Pregnenolone 17,20 Lyase DHEA Androstenediol 3β HS D Pregnanediol 8 Pregnanetriol 72 2.8 33 8 196 23 176 Progesterone CYPc17 17-OH-Progesterone 17,20 Lyase Androstenedione Testosterone CYPc21 Corticosterone Aldosterone Mineralocorticoids 4.8 1.4 14.3 5α a-thf CYP11b1 CYPc21 11-Deoxycortisol Cortisol 11βHSD 1 11βHSD 2 THF THS Cortisone THE 5β 0.16 4.85 Aromatase (CYP19) 5β 5α Androsterone 97 43 580 Etiocholanolone 122 82 765 17.2 0 24.2 5α DHT Androstanediol Aromatase (CYP19) 0.16 4.85 0.16 4.85 Estrogen Metabolites Estrone (E1) Estradiol(E2) ENZYMATIC STEPS: 3βHSD = 3beta-Hydroxysteroid dehydrogenase 5α = 5alpha-Reductase 5β = 5beta-Reductase CYP11b1 = 11beta-Hydroxylase 11βHSD = 11beta-Hydroxysteroid dehydrogenase = 17beta-Hydroxysteroid dehydrogenase 17,20 Lyase = 17,20 Desmolase CYPc17 = 17alpha-Hydroxylase CYP19 = Aromatase CYPc21 = 21-Hydroxylase ESTROGEN METABOLISM: 1A1 = Cytochrome p450 1A1 (CYP1A1) 3A4 = Cytochrome p450 3A4 (CYP3A4) 1B1 = Cytochrome p450 1B1 (CYP1B1) COMT = Catechol-O-Methyl-transferase 1B1 1.96 1.0 2.0 8.0 1A1 1.0 4.0 3A4 4-OHE1 COMT 2-MeOE1 5.17 0.83 0.4 8.6 >=0.7 16α-OHE1 Estriol (E3) 3.40 0.2 3.5 2.0 19.0 COMT 4-MeOE1 4.68 7.22 0 2.6 >=0.1
Complete Patient: SAMPLE PATIENT ID: Page 2 Male Hormones Anabolic/Catabolic Balance 17 Ketosteroids/17 Hydroxysteroids Ratio Anabolic/Catabolic Balance (FMV urine) 0.30 1.00-3.86 Catabolic (Wear & Tear) 1.0 Anabolic (Growth & Healing) Catabolic Anabolic 17-Hydroxysteroids, Total 2,067 168-1,751 nmol/dl (SG) 17-Ketosteroids, Total 612 303-2,184 nmol/dl (SG) Enzymatic Activity Estrogen Metabolism Phase 1 Phase 2 2-Hydroxyestrone/16 -Hydroxyestrone Ratio 16α-OHE1 Higher Risk of Breast Cancer Estrogen Metabolism Index 3.25 2.1 15.8 Lower Risk of Breast Cancer 2-MeOE1 Methylation Activity 2-Methoxyestrone/2-Hydroxyestrone Ratio 4-OHE1 4-MeOE1 Less Methylation >=0.2 4.22 More Methylation 1 6 α -OHE 1 5α Reductase Activity Etiocholanolone/Androsterone (E/A) Ratio More 5α-Reductase Less Cortisol 1.26 0.55 2.45 11- -HSD Index (α-thf + THF)/THE 0.52 0.59 1.42 Less 5α-Reductase More Cortisol This sample pie-chart represents the optimal balance of estrogen metabolites. The metabolites in green are considered protective, whereas metabolites in red are associated with increased risk of auto-immune disease, breast & prostate cancer. The dark line separates Phase 1 and Phase 2 detoxification pathways. Phase 1 Phase 2 4-OHE1 1 6 α -OHE 1 2-MeOE1 4-MeOE1 KEY
Complete Male Hormones (FMV) Patient: Age: 47 Sex: M MRN: SAMPLE PATIENT Order Number: Completed: November 19, 2007 Received: November 09, 2007 Collected: November 06, 2007 Progesterone Pregnanediol 8-196 nmol/dl (SG) 17-Ketosteroids DHEA Androgens 2.8-33.0 nmol/dl (SG) Androsterone 97 Etiocholanolone 122 43-580 nmol/dl (SG) 82-765 nmol/dl (SG) 11-Keto-androsterone 40-230 nmol/dl (SG) 11-Keto-etiocholanolone 101 11-Hydroxy-androsterone 170 11-Hydroxy-etiocholanolone 109 17-Ketosteroids, Total* 612 46-258 nmol/dl (SG) 43-391 nmol/dl (SG) 49-336 nmol/dl (SG) 303-2,184 nmol/dl (SG) * Sum of all values Testosterone 19.2 <= 24.2 nmol/dl (SG) Androstanediol 8-33 nmol/dl (SG) 17-Hydroxysteroids Glucocorticoids Pregnanetriol 72 allo-tetrahydrocortisol, a-thf 192 Tetrahydrodeoxycortisol, THS 54.1 Tetrahydrocortisone, THE 1,279 Tetrahydrocortisol, THF 470 17-Hydroxysteroids, Total * 2,067 23-176 nmol/dl (SG) 38-331 nmol/dl (SG) <= 7.7 nmol/dl (SG) 126-730 nmol/dl (SG) 126-559 nmol/dl (SG) 168-1,751 nmol/dl (SG) * Sum of all values Cortisol, Free 4.8 1.4-14.3 mcg/dl (SG)
Patient: SAMPLE PATIENT ID: Page 4 Estrogens Estrogens Estrone (FMV urine) 1.98 Estradiol (FMV urine) 0.90 Estriol (FMV urine) 2.90 2.0-8.0 mcg/l 1.0-4.0 mcg/l 2.0-19.0 mcg/l Estrogen Metabolites 2-Hydroxyestrone (FMV urine) 4.19 16α-Hydroxyestrone (FMV urine) 0.70 4-Hydroxyestrone (FMV urine) 5.68 2-Methoxyestrone (FMV urine) 0.09 4-Methoxyestrone (FMV urine) 6.22 0.4-8.6 mcg/l 0.1-1.3 mcg/l <=2.6 mcg/l >=0.1 mcg/l >=0.1 mcg/l Ratios Anabolic/Catabolic Balance (FMV urine) 0.30 11-β-HSD Index (FMV urine) 0.52 E/A: 5-β/5-α Ratio (FMV urine) 1.26 2-Hydroxyestrone/16α-Hydroxyestrone Ratio (FMV urine) 16.8 1.00-3.86 0.59-1.42 0.55-2.45 2.1-15.8 2-Methoxyestrone/2-Hydroxyestrone Ratio (FMV urine) 5.06 >=0.2 4-Methoxyestrone/4-Hydroxyestrone Ratio (FMV urine) 3.00 >=0.05 The performance characteristics of all assays have been verified by Genova Diagnostics, Inc. Unless otherwise noted with U.S. Food and Drug Administration, assays are For Research Use Only. as cleared by the
Patient: SAMPLE PATIENT ID: Page 5 Additional Markers Triiodothyronine, T3 (FMV urine/cr) 39.65 3.20-12.86 mcg/g Creat. Age Reference Range 21 to 30 yrs 2-80 microu/l (SG) 31 to 40 yrs 1-59 microu/l (SG) 41 to 50 yrs 1-60 microu/l (SG) 51 to 60 yrs 1-36 microu/l (SG) 61 to 70 yrs 1-33 microu/l (SG) Over 70 yrs 1-26 microu/l (SG) The performance characteristics of all assays have been verified by Genova Diagnostics, Inc. Unless otherwise noted with U.S. Food and Drug Administration, assays are For Research Use Only. as cleared by the